Beam Therapeutics (BEAM) just cleared an important clinical hurdle, with Phase 1/2 BEACON trial results for its sickle cell therapy risto cel published in The New England Journal of Medicine.
See our latest analysis for Beam Therapeutics.
At a share price of US$24.66, Beam’s recent news around risto cel and BEAM-302 comes after a mixed stretch. A 1-day share price return of 1.82% and 7-day share price return of 11.13% contrast with a 90-day share price return of 9.14% and a 5-year total shareholder return of 64.89%. This suggests long term holders have still faced meaningful volatility even as recent momentum has picked up.
If you are watching Beam’s clinical progress and want to see what else is moving in genetic medicine, it is a good moment to scan 36 healthcare AI stocks
With Beam sharing fresh clinical data, a US$2.4b market cap, a value score of 1 and a share price sitting well below the US$51.20 analyst target, the key question is whether this reflects an opportunity or if markets already price in future growth.
Most Popular Narrative: 83.6% Undervalued
With Beam Therapeutics last closing at $24.66 and the leading narrative pointing to a $150 fair value, the gap between price and expectations is wide.
The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool. By creating double-strand DNA breaks, they introduce significant risks, including unpredictable insertions, deletions, and large genomic rearrangements. Beam represents "Gene Editing 2.0". Its base editing platform is a "molecular pencil", a precision instrument that chemically rewrites a single "letter" of the genetic code without cutting the DNA backbone. This approach offers a potentially superior safety and precision profile, designed to mitigate the core risks that plague its predecessors.
Curious what kind of revenue ramp and margin profile could support that $150 view, according to davidlsander. The rNPV assumptions behind BEAM-101, BEAM-302 and cash are anything but conservative.
Result: Fair Value of $150 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this bullish story can crack if clinical readouts disappoint or if partnerships like Pfizer and Verve change in scope, timing or economics.
Find out about the key risks to this Beam Therapeutics narrative.
Next Steps
This mix of enthusiasm and caution around Beam sets the tone for the whole story, so act quickly, review the data yourself and weigh up the 2 key rewards and 3 important warning signs.
Looking for more investment ideas?
If Beam has your attention, do not stop here. Broaden your watchlist with a few focused sets of stocks that can help inform your next move.
- Target potential mispricings and hunt for companies where quality and valuation meet by scanning 59 high quality undervalued stocks.
- Prioritise resilience and capital strength by checking companies highlighted in the solid balance sheet and fundamentals stocks screener (40 results).
- Spot underfollowed opportunities before they hit the spotlight by reviewing our screener containing 25 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com